2023 World Conference on Lung Cancer (Posters)-EP07.04. Immune Cell States as Predictors of Survival in Surgically Treated Stage I Non-small Cell Lung Cancer (NSCLC)

EP07.04. Immune Cell States as Predictors of Survival in Surgically Treated Stage I Non-small Cell Lung Cancer (NSCLC) - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the role of immune cell states in predicting survival in patients with stage I non-small cell lung cancer (NSCLC) who underwent surgical treatment. The researchers collected tissue samples from NSCLC patients treated at a hospital in Munich, Germany and used a gene expression profiling panel to analyze immune-related genes. They also examined the association between gene expression data and overall survival (OS) and progression-free survival (PFS) using a Cox regression analysis. <br /><br />Out of the 190 patients included in the study, 26 had sufficient tissue material for analysis. The researchers applied the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm to both the tumor and lymph node tissues. They found that immune dysfunction in the lymph nodes had a significant impact on survival. They also identified differences in cell populations and cellular ecotypes between patients with high and low levels of immune dysfunction. <br /><br />The study concludes that TIDE scores in both the tumor and regional lymph nodes may indicate a dysfunctional immune status and can predict postoperative survival in NSCLC. The findings highlight the importance of the tumor microenvironment and the interaction between NSCLC and immune cells in determining prognosis for patients with early-stage NSCLC. Immune transcriptomics, which involves analyzing gene expression related to the immune system, could potentially be used as a predictive marker for patient outcomes. These insights into the immune response in early-stage NSCLC may help guide treatment decisions and improve patient outcomes in the future.

Asset Subtitle

Laura Sellmer

Meta Tag

Speaker Laura Sellmer

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

immune cell states

survival prediction

non-small cell lung cancer

gene expression profiling

lymph nodes

dysfunctional immune status

tumor microenvironment

immune transcriptomics

predictive marker

patient outcomes